News

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
9/17/2019
6:45 AM ET
Press Release

Zymeworks Announces New Chair of Board of Directors and Voluntary Delisting from the TSX

9/17/2019

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that Lota Zoth has been appointed as its Chair of the Board of Directors. Ms. Zoth succeeds Nick Bedford, who has retired from his functions as Chair and Board member. Mr. Bedford served as Board Chair since September 2004.

 Continue Reading
8/28/2019
5:00 PM ET
Press Release

Zymeworks to Participate in Upcoming Investor Conferences

8/28/2019

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will participate in three upcoming investor conferences.

 Continue Reading
8/2/2019
5:00 PM ET
Press Release

Zymeworks Reports 2019 Second Quarter Financial Results

8/2/2019

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the second quarter ended June 30, 2019.

 Continue Reading
7/16/2019
8:30 AM ET
Press Release

Celgene Selects Lead Oncology Therapeutic Candidate Under Bispecific Antibody Collaboration with Zymeworks

7/16/2019

First of ten potential products built on Zymeworks’ proprietary AzymetricTM platformZymeworks to receive US$7.5 million commercial license payment  

 Continue Reading
6/24/2019
10:04 AM ET
Press Release

Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Over-Allotment Option to Purchase Additional Shares

6/24/2019

VANCOUVER, Canada--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE/TSX: ZYME), a clinical stage biopharmaceutical company developing multifunctional biotherapeutics (the “Company”), announced today the closing of its previously announced underwritten public offering (the “Offering”). The Offering consisted of 7,013,892 common shares, including the exercise in full of the underwriters’ over-allotment option to purchase 1,458,336 additional shares, and, in lieu of common shares, to a certain investor, pre-funded warrants to purchase up to 4,166,690 common shares. The common shares were offered at a price to the public of US$18.00 per common share and the pre-funded warrants were offered at a price of US$17.9999 per pre-funded warrant, for aggregate gross proceeds to the Company of approximately US$201.3 million, before deducting underwriting discounts and commissions and estimated Offering expenses.

 Continue Reading
Displaying 1 to 5 (of 123 releases)